FDA Progress on Protein Standards Clears Path for Else Nutrition's U.S. Infant Formula Entry
Event summary
- FDA formally listed Protein Efficiency Ratio (PER) Rat Bioassay Study Guidance as an active topic within its Foods Program regulatory agenda on March 10, 2026.
- Else Nutrition's plant-based infant formula stands to benefit from reduced regulatory uncertainty and clearer scientific expectations for protein quality validation.
- The FDA's progress aligns with broader federal initiatives to modernize infant formula oversight, including Operation Stork Speed.
- Else Nutrition aims to leverage the regulatory clarity to enter the multi-billion-dollar U.S. infant formula market.
The big picture
The FDA's advancement of PER guidance represents a significant step toward regulatory clarity for novel infant formulas, particularly plant-based formulations. This development aligns with broader federal initiatives to modernize infant formula oversight, creating a more predictable pathway for new product approvals. Else Nutrition is well-positioned to benefit from these structural industry tailwinds, including increasing demand for clean-label and plant-based nutrition options.
What we're watching
- Regulatory Tailwinds
- How the FDA's updated PER methodology will accelerate Else Nutrition's U.S. commercialization timeline.
- Market Positioning
- Whether Else Nutrition can capitalize on increasing demand for clean-label and plant-based nutrition options.
- Investor Appeal
- The pace at which regulatory modernization will strengthen Else Nutrition's positioning with ESG-focused and growth investors.